SPOTLIGHT -
The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.
Keratoconus in a pediatric population has higher prevalence than expected
ROP: Treating and preventing blindness in preterm babies
Partners collaborate on integration of AI-supported ROP telemedicine globally
Managing a changing landscape of IRD pediatric cases
An approach to preventing progression of pediatric myopia
AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children